Publication Tanriover M, Vaccines, 2022
Dates: 2021-06-22 to 2022-01-07
Funding: Public/non profit (This research was funded, and the investigational products for the study were provided by The Health Institutes of Turkey (TUSEB).)
Conflict of interest: Yes
Multicenter / Turkey
Follow-up duration (months): *
|TURKOVAC (n = 642)
CoronaVac (n = 648)
2 IM doses of 3 mcg of TURKOVAC, 28 days apart
2 IM doses of 3 mcg of CoronaVac, 28 days apart
|Characteristics of participants
Type of participants: Healthy adults
Pregnant women: 0
Immunocompromized patients: 0
Age range: NR
|Description of participants
Adults including healthy and with stable co-morbidities with no history of COVID-19 in 8 centres in Türkiye.
|In the register
Protection Indexes of Two Vaccine Doses For Symptomatic COVID-19. [Time Frame: 2 weeks after the second dose of vaccination]: To evaluate the efficacy of two-dose regimen of TURKOVAC and two-dose regimen of CoronaVac vaccines for Real Time-PCR confirmed symptomatic COVID-19 disease.
|In the report
Protection rates of two doses of TURKOVAC and two doses of CoronaVac against RT-PCR-confirmed symptomatic COVID-19 at least 14 days after the second vaccination dose.
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
|In addition to the published article and its supplement, the study registry was used in data extraction and risk of bias assessment. Neither protocol nor statistical analysis plan was available. Preliminary analysis with data cut-off date of February 23, 2022. Authors stated, "The study was closed to recruitment far before reaching the targeted sample size as the primary outcome was attained, TURKOVAC was granted EUA, and the vaccine was integrated as an option for community vaccine roll-out." The primary outcome in the article reflects that in the registry. There is no change from the trial registration in the intervention and control treatments.